New High Blood Pressure Guidelines

The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions.

 

nuevas-guias-de-hipertension

As expected, after the findings of the SPRINT trial and other recently published studies, the treatment goal was lowered and is now below 130/80 mm Hg.


Read also: FOURIER: Evolocumab Found Beneficial for Patients with Peripheral Vascular Disease of Prior MI”.


Blood pressure (BP) levels considered “prehypertension,” according to the Seventh Joint National Committee (JNC 7), are now an “elevated BP” category for patients with systolic 120 to 129 mm Hg and diastolic less than 80 mm Hg, and stage 1 hypertension for patients with systolic 130 to 139 mm Hg and diastolic 80 to 89 mm Hg. Patients with a systolic BP above 140 mm Hg and a diastolic BP above 90 mm Hg are now encompassed in stage 2 hypertension.

 

The consequence of this reclassification is that almost half of the population (45.6%) is now deemed to have hypertension vs. 31.9% according to JNC 7 criteria.


Read also: PRESERVE: IV Bicarbonate and Oral N-Acetylcysteine Do Not Prevent Contrast-Associated Acute Kidney Injury”.


This guideline has been published online before print in Hypertension and the Journal of the American College of Cardiology, and it is the culmination of a process that started in 2013 and comprised the review of over 1000 studies. The resulting document covers the prevention, detection, evaluation, and management of high blood pressure in adults.

 

There is an emphasis on the importance of lifestyle modification, beyond the levels of blood pressure and cardiovascular risk of patients.

 

Original title: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

Reference: Whelton PK et al. Hypertension. 2017; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...